首页> 美国卫生研究院文献>AAPS PharmSci >Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical Reagents
【2h】

Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical Reagents

机译:21世纪实验室的配体结合测定:关键试剂的表征和供应建议

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Critical reagents are essential components of ligand binding assays (LBAs) and are utilized throughout the process of drug discovery, development, and post-marketing monitoring. Successful lifecycle management of LBA critical reagents minimizes assay performance problems caused by declining reagent activity and can mitigate the risk of delays during preclinical and clinical studies. Proactive reagent management assures adequate supply. It also assures that the quality of critical reagents is appropriate and consistent for the intended LBA use throughout all stages of the drug development process. This manuscript summarizes the key considerations for the generation, production, characterization, qualification, documentation, and management of critical reagents in LBAs, with recommendations for antibodies (monoclonal and polyclonal), engineered proteins, peptides, and their conjugates. Recommendations are given for each reagent type on basic and optional characterization profiles, expiration dates and storage temperatures, and investment in a knowledge database system. These recommendations represent a consensus among the authors and should be used to assist bioanalytical laboratories in the implementation of a best practices program for critical reagent life cycle management.Electronic supplementary materialThe online version of this article (doi:10.1208/s12248-012-9334-9) contains supplementary material, which is available to authorized users.
机译:关键试剂是配体结合测定(LBA)的重要组成部分,并在药物发现,开发和上市后监测的整个过程中使用。 LBA关键试剂的成功生命周期管理可以最大程度地减少由试剂活性下降引起的测定性能问题,并可以减轻临床前和临床研究中出现延迟的风险。积极的试剂管理可确保充足的供应。它还可以确保关键试剂的质量在药物开发过程的所有阶段都适合和符合预期的LBA使用。该手稿总结了LBA中关键试剂的生成,生产,表征,鉴定,记录和管理的关键注意事项,并提出了针对抗体(单克隆和多克隆),工程蛋白,肽及其缀合物的建议。在基本和可选的特性描述,有效期和储存温度以及对知识数据库系统的投资方面,针对每种试剂类型给出了建议。这些建议代表了作者之间的共识,应用于协助生物分析实验室实施关键试剂生命周期管理的最佳实践方案。电子补充材料本文的在线版本(doi:10.1208 / s12248-012-9334- 9)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号